Optibiotix Health Share Price (OPTI)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.00 -3.7% 52.00 115,515 09:06:40
Bid Price Offer Price High Price Low Price Open Price
50.00 54.00 53.00 52.00 53.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.74 -2.24 -2.49 46
Last Trade Time Trade Type Trade Size Trade Price Currency
16:15:04 O 2,840 52.641 GBX
Related Shares
Smith & Nephew (SN.), Convatec (CTEC), Widecells (WDC), Salvarx (SALV)

Optibiotix Health (OPTI) Latest News

Optibiotix Health News

Date Time Source Headline
12/10/202014:34ALNCIN BRIEF: OptiBiotix Notes Australia And New Zealand Product Launch
12/10/202007:00UKREGOptiBiotix Health PLC Launch of weight management products
09/10/202014:00RNSNONOptiBiotix Health PLC Investor presentation
08/10/202021:16ALNCUK EXECUTIVE CHANGE SUMMARY: Silence Wants US CFO After Nasdaq Float
08/10/202007:00RNSNONOptiBiotix Health PLC Head of Quality & Operations appointment
06/10/202014:36ALNCIN BRIEF: OptiBiotix's ProBiotix Inks Singaporean Deal For CholBiomeX3
06/10/202007:00RNSNONOptiBiotix Health PLC Exclusive distribution agreement
05/10/202011:05UKREGOptiBiotix Health PLC Second Price Monitoring Extn
05/10/202011:00UKREGOptiBiotix Health PLC Price Monitoring Extension
02/10/202011:13ALNCOptiBiotix Notes FDA Approval For Investigation Into Partner's New Drug
More Optibiotix Health News
Optibiotix Health Investors    Optibiotix Health Takeover Rumours

Optibiotix Health (OPTI) Discussions and Chat

Optibiotix Health Forums and Chat

Date Time Title Posts
22/10/202022:04OptiBiotix - The uncensored thread 32,220
22/10/202017:15OptiBiotix Health PLC - 10,533
20/10/202005:11OptiBiotix Health (Facts NOT Fiction)5,280
11/10/202000:03SentimentalRules AKA idoflykathy76
10/6/202012:27OptiBiotix Health PLC - Products & Partner Listings7

Add a New Thread

Optibiotix Health (OPTI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:15:0652.642,8401,495.00O
15:04:1752.649449.48O
15:02:0052.645,2812,779.97O
14:48:3352.647,3483,868.06O
14:33:1650.8220,00010,163.00O
View all Optibiotix Health trades in real-time

Optibiotix Health (OPTI) Top Chat Posts

DateSubject
22/10/2020
09:20		Optibiotix Health Daily Update: Optibiotix Health Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 54p.
Optibiotix Health Plc has a 4 week average price of 51.50p and a 12 week average price of 47p.
The 1 year high share price is 72p while the 1 year low share price is currently 24p.
There are currently 87,940,601 shares in issue and the average daily traded volume is 280,165 shares. The market capitalisation of Optibiotix Health Plc is £45,729,112.52.
Read Full Thread
Reply
22/10/2020
06:30		bobdown2: This share price stayed along time above 80 pence and the business has moved forward immensely. Was the investors night enough to take the share price back up to these levels. From here it would be a 50& gain.
Read Full Thread
Follow
Reply
21/10/2020
22:11		bobdown2: An investors evening brings together high net worth individuals and companies and gives them the full share price on the company's business and future prospects. No amount of ignorant posts on this thread will stop the buying that will come from a completely different direction. Check out todays trades which includes a 25k buy. Buy if you think the buying will lead to a higher share price and start to reflect the progress made.
Read Full Thread
Follow
Reply
21/10/2020
19:55		manc10: OptiBiotix partners US firm for large scale manufacturing of SweetBiotix products Press Release September 15, 2020 LONDON: OptiBiotix Health, a life sciences business, has entered into an agreement with a US company for the purpose of large scale manufacture and commercialisation of a number of SweetBiotix products, a news release said. The agreement grants the US Company an exclusive worldwide license in return for it bearing the costs relating to product manufacturing, marketing, and all future costs relating to the commercialisation of a number of SweetBiotix products. OptiBiotix will receive a modest six-figure payment from the Company on signing the agreement and at 12 monthly intervals until product launch. Additional similar payments will be due on product launch plus royalties on all future product sales. Enhanced royalty payments will be made to OptiBiotix on sale of SweetBiotix products by the Company to 11 application/innovation partners with whom OptiBiotix has been in long term discussions regarding exploring the use of SweetBiotix products in dairy, cereal and beverage applications. The US Company requires its identity and certain commercial terms of the agreement to remain confidential to protect its commercial launch plans. Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce this agreement for SweetBiotix, a family of products based on the concept of creating a sweet fibre with a low glycaemic index which enhances the microbiome. The agreement allows the US Company to invest in the large scale manufacture and commercialisation of a number of SweetBiotix products in return for upfront, annual and product launch milestone payments, plus royalties on all future product sales. “With concerns over the amount of sugar and lack of fibre in consumer diets creating high levels of diabetes and obesity, this agreement brings closer the prospect of replacing ‘unhealthyR17; sugars with healthy sweet fibres which contain no calories and improving microbiome diversity and the benefits of SweetBiotix technology to a global audience.” OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome – the collective genome of the microbes in the body – in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The current areas of focus for the business include obesity, cardiovascular health, and diabetes.
Read Full Thread
Follow
Reply
21/10/2020
19:51		manc10: The "SweetBiotix®: Scientific and commercial update" announcement released on 27 March 2019 at 7.00am under RNS No 0786U was released with incorrect text and should be disregarded. The below is the correct text. OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, provides the following scientific, manufacturing and commercial update on its sweet fibre (SweetBiotix®) technology platform. Scientific Update OptiBiotix has a number of development programmes creating natural sweet fibres (SweetBiotix®) with the potential to meet the needs of both the natural high intensity sweetener and bulk sugar markets. These markets are collectively forecast to reach $112bn by 2022 (Mordor Intelligence, 2017). OptiBiotix's products are differentiated from other natural sweeteners and sugar substitutes on the market in that they been developed:- i. To be dietary fibres proving no contribution to sugar intake ii. Have low glycemic index iii. Enhance the gut microbiome providing additional potential health benefits iv. Have intense sweetness (High Intensity Sweeteners) or sweetness similar to sugar (depending on product) Recent gut model studies have shown that OptiBiotix's high intensity derived sweeteners enhance the gut microbiome, significantly increasing the number and activity (short-chain fatty acids -SCFA) of bacterial species typically associated with good gut health when compared to current natural sweeteners (e.g. stevia, mogrosides). SCFA's are the body's molecular messengers widely known for their importance in gut health & immunity and are one of the main ways in which the gut microbiome contributes to better health. These results, presented at ProBiota 2019 (RNS: 20 February 2019), are to the best of our knowledge, the first reports of high intensity derived sweeteners impacting on the gut microbiome. This functionality, published at a major scientific conference, has stimulated interest from a wider range of partners looking for functionality and health benefits in their products. Commercial Update The Company has a strategy of creating interests and commercial agreements with multiple companies who have expertise in the manufacture and application development of high value speciality ingredients. This has led to agreements with two companies (RNS: 31 May 2018 and 26 June 2018) looking to explore the potential to reduce the sugar content in a range of applications, including dairy. In addition to ongoing discussion with existing partners, OptiBiotix has reached non-binding Heads of Terms with a US company to license OptiBiotix's high intensity derived sweeteners. This company has funded the pilot scale up and supply of two batches of high intensity derived sweeteners. Once a binding commercial agreement has been reached, this will be announced to the market. Late stage discussions are ongoing with another global partner to jointly develop a finished product which allows claim for sugar and calorie reduction whilst limiting any cost increase in the final product to 10%. These discussions with multiple, often competing partners, are taking place against a background of continued development of the science which is identifying new functionalities and creating new opportunities. This creates a complexity in negotiating separate manufacturing and application rights for both high intensity sweeteners, bulk sugars and combinations of both. These discussions are with corporate partners within a corporate process and timescale, and are often subject to strict confidentiality clauses.
Read Full Thread
Follow
Reply
20/10/2020
14:13		spartan attack: I think opti should decide to be generous, and at board level, decide that the faithful opti holders Deserve a placing offered to them at 0.5% discount. Market it as “A Thank you” Just before share price collapses....
Read Full Thread
Follow
Reply
18/10/2020
11:57		manc10: This content is copyright protectedHowever, if you would like to share the information in this article, you may use the headline, summary and link below:'Designer prebiotics' are the future of food and microbiome modulation, says expert02-May-2019 By Nikki Cutler'Designer prebiotics' have greater potential than probiotics to be able to modify our microbiomes and improve our long-term health, according to the founder and CEO of a trailblazing life science firm.HTTPS://WWW.NUTRAINGREDIENTS-ASIA.COM/ARTICLE/2019/05/02/DESIGNER-PREBIOTICS-ARE-THE-FUTURE-OF-FOOD-AND-MICROBIOME-MODULATION-SAYS-EXPERT ×?HomeNews NewsResearchRegulation & PolicyManufacturersSuppliersMarkets and TrendsViewsPromotional FeaturesRegions RegionsAll Asia-PacificEast AsiaSouth AsiaSouth East AsiaOceaniaSectors SectorsSupplementsFunctional foodsWhole foodsDairyBaked goods, snacks & sweetsBeveragesSports NutritionInfant and children's nutritionMedical NutritionTrends TrendsCOVID-19Health claimsOmega-3ProbioticsFinancial playsBotanicalsPhoodHealth HealthAllergies & intolerancesBeauty from withinBlood sugar managementBone & joint healthCancer risk reductionCardiovascular healthCognitive functionEnergyEye healthGut/digestive healthHealthy ageingImmune supportInflammationMaternal & infant healthMen's HealthOral/Gum healthRespiratory healthSkin healthSports nutritionWeight managementWomen's healthResources ResourcesAntioxidants/carotenoidsBotanicals & HerbalsDairy-based ingredientsDosage forms & delivery formatsFibres & carbohydratesMineralsNutricosmeticsOmega-3s & Nutritional oilsPolyphenolsProbiotics and prebioticsProteins, peptides, amino acidsSoya-based ingredientsVitamins & premixesChina ??Japan ??Events EventsAll EventsOnline EventsEditorial WebinarsShows & ConferencesAll EventsResources ResourcesProduct innovationsTechnical PapersProduct BrochuresVideos & AudioSupplier WebinarsSuppliersReports ReportsProbiotic e-commerce: Market size and brand share insights across 20 marketsProbiotics by target population – Strategic product roadmap fact sheetsImmunity, inflammation, oral health and respiratory probioticsProbiotics & the First 1000 Days nutrition: 25-market analysisSkinbiotics: Probiotics for skin health, eczema, allergies & moreView All ReportsSign up to our newslettersGrowth AsiaSearch'Designer prebiotics' are the future of food and microbiome modulation, says expert ?istock | xuanhuonghoBy Nikki Cutler02-May-2019 - Last updated on 03-May-2019 at 10:14 GMT'Designer prebiotics' have greater potential than probiotics to be able to modify our microbiomes and improve our long-term health, according to the founder and CEO of a trailblazing life science firm.In the same week that his company's CE marked weight management prebiotic supplement Slimbiome Medical hits the UK market, Stephen O'Hara, founder and CEO of Optibiotix Health plc, points out the huge potential for the current underdog of the microbiome health industry.He told NutraIngredients: "We think prebiotics is the bigger opportunity for the future and that's the area we are putting a lot of investment into.?"A probiotic is transient. It goes in the gut, it has billions of bacteria around it and its survival is short term.?"A prebiotic approach, giving foodstuff to the good bacteria and building it internally, will have a longer-term effect."?He adds that, commercially, prebiotics can have a greater opportunity for impact on consumers' diets due to the ability to incorporate them into a wider range of applications."Probiotics tend to have a limited shelf life and they aren't heat stable so they can't be added to any baked products, for example. Whereas prebiotics can be added to breads, yogurts, snack bars, you name it.?"Also, most manufacturers don't want to introduce bacteria into their manufacturing facility making it hard to incorporate these into other food stuffs."?Two thirds of Optibiotix' new SlimBiome supplement is composed of prebiotics, which work to increase microbial diversity and increase growth of the specific bacteria associated with leanness.But weight management is just one of number of potential targeted health benefits for 'designer prebiotics', says O'Hara."Currently people use prebiotics for a general health benefit but we are trying to demonstrate how it can be used for targeted health such as anxiety reduction, cardiovascular health and even cancer.?"Our R&D teams have used gut models to demonstrate the ability of our microbiome modulators ?to increase the growth rate, biological activity, and health effect, of specific microbial species in the human microbiome. ?"This has now been demonstrated in multiple species, including OptiBiotix's cholesterol reducing strain (LPLDL?). To our knowledge, this is the first time this effect has been demonstrated and creates the opportunity for designer prebiotics which can modulate targeted elements of the microbiome."?He also argues that prebiotics for the elderly is one particularly opportune yet untapped area."Most prebiotics are consumed by infants through their milk as we understand the importance of helping build their microbiomes from an early age.?"It's well established that people have a narrower microbial spectrum when they are very young and when they are very old.?"If we are ensuring to give babies prebiotics, why can't we use them in the elderly population who will benefit massively."?OptiBiotix product pipeline?SlimBiome Medical is a CE marked Medical Device, and is one of a number of products commercialised by the UK-based firm to manage weight and cardiovascular risk in a series of microbiome-based products currently under development.These include CardioBiome, shown to reduce total cholesterol by 22% in gut models, ImmunoBiome, designed to improve immune health and reduce allergy symptoms, and WellBiome, designed to improve cognitive health and reduce anxiety and stress related conditions.OptiBiotix manufactures SlimBiome in Europe with its partner Nutrlinea, and in India, with its partner Zeon, based on the outskirts of New Delhi. Both partners are in dustry leaders in their field and able to develop and manufacture customised formulations and presentations (spray dried and dry blended powders, syrups, capsules, tablets, sachets and diskettes) for the food, herbal, pharmaceutical and nutraceutical Industry. slartybartfaster
Read Full Thread
Follow
Reply
18/10/2020
11:49		spartan attack: Ahh sort of ties in to speculation of opti share price maturing 2025 be a good idea to speculate there is lots of potential here to that date i guess
Read Full Thread
Follow
Reply
18/10/2020
11:17		slartybartfaster: ‘Designer prebiotics’ are the future of food and microbiome modulation, says expert 02-May-2019 By Nikki Cutler ‘Designer prebiotics’ have greater potential than probiotics to be able to modify our microbiomes and improve our long-term health, according to the founder and CEO of a trailblazing life science firm. HTTPS://WWW.NUTRAINGREDIENTS-ASIA.COM/ARTICLE/2019/05/02/DESIGNER-PREBIOTICS-ARE-THE-FUTURE-OF-FOOD-AND-MICROBIOME-MODULATION-SAYS-EXPERT  Probiotic e-commerce: Market size and brand share insights across 20 markets Probiotics by target population – Strategic product roadmap fact sheets Immunity, inflammation, oral health and respiratory probiotics Probiotics & the First 1000 Days nutrition: 25-market analysis Skinbiotics: Probiotics for skin health, eczema, allergies & more View All Reports Sign up to our newsletters Growth Asia Search ‘Designer prebiotics’ are the future of food and microbiome modulation, says expert     ?istock | xuanhuongho By Nikki Cutler 02-May-2019 - Last updated on 03-May-2019 at 10:14 GMT ‘Designer prebiotics’ have greater potential than probiotics to be able to modify our microbiomes and improve our long-term health, according to the founder and CEO of a trailblazing life science firm. In the same week that his company’s CE marked weight management prebiotic supplement Slimbiome Medical hits the UK market, Stephen O’Hara, founder and CEO of Optibiotix Health plc, points out the huge potential for the current underdog of the microbiome health industry. He told NutraIngredients: “We think prebiotics is the bigger opportunity for the future and that’s the area we are putting a lot of investment into.? “A probiotic is transient. It goes in the gut, it has billions of bacteria around it and its survival is short term.? “A prebiotic approach, giving foodstuff to the good bacteria and building it internally, will have a longer-term effect.”? He adds that, commercially, prebiotics can have a greater opportunity for impact on consumers’ diets due to the ability to incorporate them into a wider range of applications. “Probiotics tend to have a limited shelf life and they aren’t heat stable so they can’t be added to any baked products, for example. Whereas prebiotics can be added to breads, yogurts, snack bars, you name it.? “Also, most manufacturers don’t want to introduce bacteria into their manufacturing facility making it hard to incorporate these into other food stuffs.”? Two thirds of Optibiotix’ new SlimBiome supplement is composed of prebiotics, which work to increase microbial diversity and increase growth of the specific bacteria associated with leanness. But weight management is just one of number of potential targeted health benefits for ‘designer prebiotics’, says O’Hara. “Currently people use prebiotics for a general health benefit but we are trying to demonstrate how it can be used for targeted health such as anxiety reduction, cardiovascular health and even cancer.? “Our R&D teams have used gut models to demonstrate the ability of our microbiome modulators ?to increase the growth rate, biological activity, and health effect, of specific microbial species in the human microbiome. ? “This has now been demonstrated in multiple species, including OptiBiotix’s cholesterol reducing strain (LPLDL?).  To our knowledge, this is the first time this effect has been demonstrated and creates the opportunity for designer prebiotics which can modulate targeted elements of the microbiome.”? He also argues that prebiotics for the elderly is one particularly opportune yet untapped area. “Most prebiotics are consumed by infants through their milk as we understand the importance of helping build their microbiomes from an early age.? “It’s well established that people have a narrower microbial spectrum when they are very young and when they are very old.? “If we are ensuring to give babies prebiotics, why can’t we use them in the elderly population who will benefit massively.”? OptiBiotix product pipeline? SlimBiome Medical  is a CE marked Medical Device, and is one of a number of products commercialised by the UK-based firm to manage weight and cardiovascular risk in a series of microbiome-based products currently under development. These include CardioBiome, shown to reduce total cholesterol by 22% in gut models, ImmunoBiome, designed to improve immune health and reduce allergy symptoms, and WellBiome, designed to improve cognitive health and reduce anxiety and stress related conditions. OptiBiotix manufactures  SlimBiome in Europe with its partner Nutrlinea, and in India, with its partner Zeon, based on the outskirts of New Delhi. Both partners are in dustry leaders in their field and able to develop and manufacture customised formulations and presentations (spray dried and dry blended powders, syrups, capsules, tablets, sachets and diskettes) for the food, herbal, pharmaceutical and nutraceutical Industry.
Read Full Thread
Follow
Reply
14/10/2020
11:01		manc10: nd product royalties. The myth here is OPTI needs cash to promote and distribute here, thus cash is a burden on OPTI. This is a fundamental failure to understand the model. OPTI's partners market the products. This part of the business is difficult to get to grips with royalties from retail-end partners. These typically range from 25% to 40% and in some cases may require OPTI to take part in in-store discounted promotions for their own products. An example of this is the recent launch of Slimbiome with Holland & Barratts 25% discount for the first month. hTTps://www.hollandandbarrett.com/shop/brands/slimbiome/ hTTps://www.dailymail.co.uk/femail/article-7892183/How-commit-slimming-shaping-without-fuss.html More in-depth business models hTTps://lemminginvestors.blogspot.com/2018/06/optibiotix-commercial-strategy.html Overview of Partners and products. It does need updating hTTps://lemminginvestors.blogspot.com/2018/11/optibiotix-partners-and-products-as-nov.html A point to remember. Typically, larger corporates can take 12-18 months to develop a new product from scratch. Others move much more quickly. If you track back through the RNS reports, this should give you an idea of the potential there is for partner product launches. OPTI has had 3 large partner launches in January, just one of them is expected to make the company profitable at group level by FY 2020. For management interviews, and detailed information on OPTI and other companies, use the search facility on the right of the blog link; hTTps://lemminginvestors.blogspot.com/ SCIENCE VALIDATION hTTps://optibiotix.online/pages/lpldl-science hTTps://optibiotix.online/pages/slimbiomescience hxxps://app.oxfordabstracts.com/events/696/program-app/submission/125583 FY 2019 trading update - Results in April OptiBiotix has launched successful products with 3 major corporates in January, with better sales than expected, have products on sale in more than 30 countries around the world, are rapidly growing revenues to profitability. The biggest risk is retail shareholders who feed off panic and speculation undermining this tangible progress creating a run on the share price This is exaggerated when there is other market volatility. The innumerate argue OptiBiotix is running out of cash fast, the reality is the polar opposite. The £514,000 (sales invoice not yet paid subject to terms at the time of FY period end) figure can be tagged on to the £808,000 figure equating to £1.322,000 in FY 2019. At the time of the trading update in January, 50% of the £514,000 had been paid, it is not a stretch to imagine the remainder has been paid or will arrive in Q1. Will PLC cost under £1.2 million PA and R&D as well as IP cost reduction, there is every chance this will reduce or off-set additional sales executive. We are a mere three months into Q1 and already have three new partner products launched in January 2020, which will add significant cash flow to the bottom line if we assume H1 has accelerated from H1 2019 figure of £158,000. My view is c£600,000 in H1 2020 subject to invoice T&C - H2 remains heavily weight due to accounting/invoices landing in this period. It is my view OptiBiotix is fully funded for existing business plans, and therefore there is no need sell-down of an important asset, that is SkinBioTherapeutics, but as always, the caveat is businesses develop and business needs can change.
Read Full Thread
Follow
Reply
14/10/2020
10:18		spartan attack: Not quiet on opti share price It’s as if forward selling into a placing imo
Read Full Thread
Follow
Reply
Optibiotix Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
OPTI
Optibiotix..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201022 21:38:12